Prothena (PRTA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Annual General Meeting scheduled for May 14, 2026, in Dublin, Ireland, with voting available online or in person.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of two directors, Shane M. Cooke and Dennis J. Selkoe, to serve until the 2029 AGM unless earlier disqualified.
Ratification of KPMG LLP as independent auditor for fiscal year 2026, with audit committee authorized to set remuneration.
Advisory vote on executive compensation for named executive officers.
Provision for other business to be transacted as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and auditor ratification.
Latest events from Prothena
- Director elections, auditor ratification, and executive pay are key focus areas, with strong governance oversight.PRTA
Proxy filing27 Mar 2026 - Major phase III programs advance, with strong milestone payments and CYTOPE platform progress.PRTA
The Citizens Life Sciences Conference 202611 Mar 2026 - Advancing late-stage neuro and amyloid therapies with major milestones and strong partnerships.PRTA
Corporate presentation11 Mar 2026 - Advanced late-stage pipeline, strong cash, and 2026 focus on milestones and share redemption.PRTA
Q4 202519 Feb 2026 - Advancing late-stage neuro and amyloid programs with key readouts and commercialization plans ahead.PRTA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Streamlined for partnerships, major phase 3 milestones and shareholder returns are expected in 2026.PRTA
Cantor Global Healthcare Conference 202531 Dec 2025 - Strong cash reserves and pivotal clinical milestones expected in 2025.PRTA
Q4 202429 Dec 2025 - Advancing late-stage neuro and cardiac programs with major milestones and financial upside ahead.PRTA
Piper Sandler 37th Annual Healthcare Conference11 Dec 2025 - Phase III neurology trials advance, with transferrin tech and key data expected by 2027.PRTA
Evercore ISI 8th Annual HealthCONx Conference7 Dec 2025